Retinal Vein Occlusion Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

October 12 20:31 2022
Retinal Vein Occlusion Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Retinal Vein Occlusion Market
DelveInsight’s ‘Retinal vein occlusion Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Retinal vein occlusion, historical and forecasted epidemiology as well as the Retinal vein occlusion market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

elveInsight’s ‘Retinal vein occlusion Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Retinal vein occlusion, historical and forecasted epidemiology as well as the Retinal vein occlusion market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The Retinal vein occlusion market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Retinal vein occlusion market size from 2019 to 2032. The Report also covers current Retinal vein occlusion treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the Key Facts of the Retinal Vein Occlusion Market Report:

  • RVO is more frequent in the older age population. The age-specific diagnosed prevalent cases in the 7MM were approximately 454,378, 572,552, and 491,279 cases for the age group less than 65 years, 65─74 years, and ≥75 years, in 2021.
  • In the 7MM, total type-specific diagnosed prevalent cases of RVO were approximately 298,789 cases for CRVO and 1,219,419 cases for BRVO in the year 2021. As per the analysis, these cases are expected to increase by the year 2032.
  • Among EU5, Germany has the largest patient population of RVO. Spain has the lowest patient population of RVO among the 7MMThe US has the highest percentage of RVO patient pool.
  • This increase in market size will be the result of the expected launch of potential therapies and an increase in the diagnosed prevalent population of RVO in the 7MM

Key Benefits of the Retinal Vein Occlusion Report

  • The report covers the descriptive overview of Retinal vein occlusion, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Retinal vein occlusion epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Retinal vein occlusion is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Retinal vein occlusion market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Retinal vein occlusion market.

Got queries? Click here to know more about the Retinal Vein Occlusion Landscape

Retinal Vein Occlusion Overview

Retinal vein occlusion (RVO), the second most common retinal vascular disorder after diabetic retinopathy is an obstruction of the retinal venous system by thrombus formation and may involve the central, Hemi-central, or branch retinal vein. The most common etiological factor is compression by adjacent atherosclerotic retinal arteries. Other possible causes are external compression or disease of the vein wall, e.g., vasculitis. 

The primary symptom is a sudden vision change. It could include blurry vision or a partial or complete loss of vision. Persistent bruising and swelling of the macula are associated with permanent loss of central vision. This swelling is caused by damaged blood vessels that leak fluid. These symptoms usually occur in one eye and are often painless and could be short-term or permanent, depending on how quickly the patient seeks treatment and other health conditions. The most recognized risk factors for RVO are age and systemic vascular disorders. 

In over half of the cases, the age of onset is over 65 years. However, patients under 45 can also develop an RVO in some cases. Other risk factors include systemic conditions like hypertension, arteriosclerosis, diabetes mellitus, hyperlipidemia, cerebral vascular stroke, blood hyperviscosity, and thrombophilia. 

Retinal Vein Occlusion Epidemiological Insights

  • In the year 2021, the total prevalent cases of RVO were approximately 2,708,118 cases in the 7MM, which are expected to increase by 2032 at the CAGR of 1.0% during the study period (2019–2032).
  • Among EU-5 countries, the highest number of prevalent cases of RVO was in Germany (approximately 225,397 cases) in the year 2021, which is expected to increase by 2032. The lowest number of cases was observed in Spain.
  • In 2021, the total diagnosed prevalent cases of RVO in the 7MM were approximately 1,518,208 cases, which are estimated to increase by 2032 at the CAGR of 1.4% during the study period (2019-2032).
  • In the 7MM, total gender-specific diagnosed prevalent cases of RVO were approximately 715,167 cases for males and 803,041 cases for females in the year 2021. As per the analysis, these cases are expected to increase by the year 2032.

Retinal Vein Occlusion  Epidemiological Segmentation 

  • Total Retinal Vein Occlusion prevelant cases
  • Total Retinal Vein Occlusion diagnosed prevalant cases
  • Total Retinal Vein Occlusion diagnosed age-specific cases 
  • Total Retinal Vein Occlusion diagnosed gender-specific cases

Retinal Vein Occlusion Market Outlook 

The current treatment options for Retinal vein occlusion intend to minimize the damage, as there is no treatment to improve vision loss in the long term. The therapies aim to prevent further visual loss and its complications, such as macular edema, ischemia, or neovascularization. 

 

Laser treatment may be used along with anti-VEGF therapy in hard-to-treat cases. Laser therapy for macular edema involves applying light laser pulses to the macula in a grid pattern. Pan-retinal photocoagulation therapy is a treatment option used when patients have new blood vessel formation following the Retinal vein occlusion. While Focal laser therapy is used to treat associated edema. Several other treatment strategies focus on the surgical treatment of the occluded retinal vein. 

 

Some of the approaches include radial optic neurotomy, chorioretinal venous anastomosis, vitrectomy with or without internal limiting membrane peeling, and others. According to DelveInsight, the overall dynamics of the Retinal vein occlusion market are anticipated to change in the coming years owing to the expected launch of emerging therapies.

 

Learn more by requesting for sample @ Retinal Vein Occlusion Market

Retinal Vein Occlusion Key Companies

  • Taiwan Liposome Company
  • Aerie Pharmaceuticals
  • Graybug Vision
  • Outlook Therapeutics
  • And others

 

Retinal Vein Occlusion Therapies

  • TLC399
  • AR-1105
  • GB-102
  • ONS-5010 (Lytenava)
  • And others.

 

Table of Contents

 

  •   Key Insights 
  •   Report Introduction 
  •   Executive Summary of Retinal Vein Occlusion   
  •   Disease Background and Overview
  •   Epidemiology and patient population
  •   The United States 
  •   EU 5
  •   Retinal Vein Occlusion  Emerging Therapies
  •   Retinal Vein Occlusion Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •  Retinal Vein Occlusion Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer
  •  About DelveInsight

Click here to read more about Retinal Vein Occlusion

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/